Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole
D. Tu, K. I. Pritchard, H. B. Muss, L. E. Shepherd, Timothy J. Whelan, S. Martino, J. N. Ingle, R. B. Livingston, N. J. Robert, David Cameron, E. A. Perez, N. E. Davidson, Yanin Chavarri-Guerra, P. E. Goss
Abstract
MA17 showed improved outcomes in postmenopausal women given extended letrozole (LET) after completing 5 years of adjuvant tamoxifen.
Topics & Concepts
LetrozoleMedicineBreast cancerPlaceboGynecologyOncologyAdjuvantInternal medicineCancerObstetricsTamoxifenAlternative medicinePathologyBreast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesEstrogen and related hormone effects